Pfizer Inc. and Samsung Medical Center said Wednesday they started a collaboration to do research on liver cancer.
The companies said they formed a partnership in June and will analyze tumors from patients in Korea. They plan to make genetic profiles that could help physicians select which therapy to use on similar patients.
New York-based Pfizer is the world's largest drugmaker in terms of revenue. Its products include the kidney cancer drug Sutent. In April it stopped a late-stage study of Sutent as a treatment for liver cancer because patients were not living as long as people who were on a competing drug, and they were more likely to suffer serious side effects.
Pfizer agreed to invest $300 million in Research and Development in South Korea in 2007, and formed a partnership with the Korea Research Institute of Bioscience and Biotechnology at the time.
Shares of Pfizer fell 9 cents to $14.70 in morning trading.
Subscribe to:
Post Comments (Atom)
Posts
No comments:
Post a Comment